Skip to search formSkip to main contentSkip to account menu

sipuleucel-T

A cell-based vaccine composed of autologous antigen-presenting peripheral blood mononuclear cells (enriched for a dendritic cell fraction) that have… 
National Institutes of Health

Related topics

Related topics

13 relations
250 ML sipuleucel-T 200000 CELLS/ML Injection250 ML sipuleucel-T 200000 CELLS/ML Injection [Provenge]ACPP protein, humanAntigen Sensitization

Narrower (2)

APC 8015Provenge

Broader (1)

Tissue Extracts

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Survival Outcomes of Sipuleucel-T Phase III Studies: Impact of Control-Arm Cross-Over to Salvage Immunotherapy
Control-arm patients from three prostate cancer clinical trials of sipuleucel-T (an autologous APC–based therapy) received APC… 
2015
2015
Sipuleucel-T for the Treatment of Patients With Metastatic Castrate-resistant Prostate Cancer: Considerations for Clinical Practice.
Sipuleucel-T treatment is associated with a significant and consistent survival benefit in patients with metastatic castrate… 
Review
2014
Review
2014
Optimizing Dendritic Cell-Based Approaches for Cancer Immunotherapy
Dendritic cells (DC) are professional antigen-presenting cells uniquely suited for cancer immunotherapy. They induce primary… 
2013
2013
Randomized phase II trial evaluating the optimal sequencing of sipuleucel-T and androgen-deprivation therapy (ADT) in patients (pts) with biochemically recurrent prostate cancer (BRPC).
34 Background: ADT is a standard therapy for pts with BRPC after failure of primary therapy, and has known immunomodulatory… 
Review
2012
Review
2012
An overview of sipuleucel-T: Autologous cellular immunotherapy for prostate cancer
Sipuleucel-T, the first autologous active cellular immunotherapy approved by the United States Food and Drug Administration, is… 
Review
2012
Review
2012
Development of novel immune interventions for prostate cancer.
2012
2012
Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer.
Vol. 104, Issue 18 | September 19, 2012 References 1. Huber ML, Haynes L, Parker C, Iversen P. Interdisciplinary critique of… 
2011
2011
Fresh from the biologic pipeline—2010
Apart from a drug produced in rabbits, 2010 was in some ways an unremarkable year for biologic drugs coming onto the market… 
2011
2011
Characterization of antigen-specific T-cell activation and cytokine expression induced by sipuleucel-T.
155 Background: Sipuleucel-T (Provenge) is an autologous cellular immunotherapy designed to stimulate an immune response in men… 
Review
2008
Review
2008
Sipuleucel-T for the treatment of prostate cancer.
Patients with cancer have deficiencies in the number and function of dendritic cells. Loaded dendritic cell therapies attempt to… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)